Ilduc Duo

Quick links to important sections

Ilduc Duo

Method of action: Antihypertensive

Treatment option: Hypertension

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ilduc Duo

Property Description
Active ingredients Amlodipine, Benazepril
Form Oral Capsule
Pharmacological class Antihypertensive
General purpose Management of high blood pressure
Origin Synthetic

Ilduc Duo is a prescription-only synthetic drug classified pharmacologically as an Antihypertensive medicine, used to help manage elevated blood pressure. The medication is administered via the oral route in an oral capsule form. This product is defined as a fixed-dose combination because it contains two distinct active ingredients in a single unit, a strategy often associated with improved patient adherence. The general purpose of this specific dual-ingredient approach is to achieve a more potent and convenient therapeutic effect than either component alone.

Composition: A Dual-Action Strategy

The core components of Ilduc Duo are Amlodipine and Benazepril, which belong to two major classes of cardiovascular drugs. Amlodipine is a dihydropyridine Calcium Channel Blocker (CCB), and Benazepril is an Angiotensin-Converting Enzyme (ACE) Inhibitor. The combination of Amlodipine/Benazepril is also commercially available under other trade names, such as Lotrel and Amlobenz, demonstrating the recognized efficacy of this specific dual mechanism.

The combined action of a CCB and an ACE Inhibitor is effective for suppressing multiple physiological pathways contributing to high blood pressure. This dual-component approach is used for achieving a multi-modal defense against vascular constriction and resistance, supporting the circulatory system and reducing the workload on the heart.

What side effects are possible with Ilduc Duo?

Possible side effects and safety information

The official safety profile for Ilduc Duo (Amlodipine/Benazepril) is defined by categories of adverse reactions and specific regulatory warnings documented in government sources.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on their incidence in clinical trials. Common reactions, typically occurring in 1% to 10% of patients, include cough, headache, dizziness, and edema (peripheral swelling).

Reactions are grouped by the physiological system affected, such as Nervous System Disorders (headache, dizziness), Respiratory Disorders (cough), and General Disorders (swelling and fatigue).


Serious Adverse Reactions and Safety Constraints

The regulatory labeling includes formal warnings for serious reactions. The most clinically significant risks are Angioedema, which is rapid, potentially life-threatening swelling of the face, throat, or intestines, and Fetal Toxicity. The medication carries a serious warning that use during the second and third trimesters of pregnancy can cause injury or death to the fetus, leading to its contraindication in pregnancy.

Additional safety constraints are present for specific groups. Patients with a history of Angioedema or those with severe renal impairment have specific safety considerations. The label also documents that African-American patients have a higher documented incidence of Angioedema compared to nonblack patients. Rare but serious risks, such as symptomatic hypotension (low blood pressure) and hepatic failure, are also documented safety concerns.

The timing of certain serious events is noted, such as the potential for Angioedema to occur early in treatment or, less commonly, after months of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Amlodipine/Benazepril (Ilduc Duo) overdose focuses on severe hemodynamic instability and mandated emergency actions. The most serious and officially documented clinical manifestation of overdose is profound and prolonged systemic hypotension (low blood pressure) resulting from excessive peripheral vasodilation.

Documented Manifestations and Severe Outcomes

Classification Manifestation/Outcome
Cardiovascular Effects Profound hypotension, reflex tachycardia, potential for systemic shock and circulatory collapse
Renal/Electrolyte Effects Potential for acute renal failure, hyperkalemia (elevated potassium)

Emergency Actions and Supportive Management

Regulatory documentation requires that patients seek emergency medical attention immediately in the event of a suspected overdose. The official prescribing information states that no specific antidote is known for the Amlodipine component.

Treatment is symptomatic and supportive, and managing severe hypotension is the priority. This management may include placing the patient in a supine position, fluid volume expansion using intravenous saline solution, and the potential need for vasopressor agents if hypotension persists. Due to the long half-life of Amlodipine, extended clinical monitoring may be required.

Therapeutic Uses of Ilduc Duo

Ilduc Duo (Amlodipine/Benazepril) is commonly used to manage blood pressure elevations and supports therapeutic control within a broad management plan. The medication is utilized to address the condition of high blood pressure, which is associated with noticeable physiological strain on the systemic network.


The primary therapeutic domains involve the treatment of chronic essential hypertension in adults, and it is relevant in contexts where supportive symptom management is appropriate. This dual-component approach is applied when additional management is required to reduce persistently high systolic and diastolic measurements, assisting with maintaining functional stability. The primary support provided is the sustained management of elevated pressure, which helps ease the overall symptom burden and may contribute to supporting better outcomes related to cardiovascular events. The medication may assist with managing symptoms linked to organ-specific functional stress.


Quick Fact: Management for Persistent High Blood Pressure The medication is relevant in contexts involving heightened systemic burden, applied across therapeutic areas where supportive symptom management is appropriate for chronic conditions.

Regulatory References

  1. NIH MedlinePlus overview of Amlodipine and Benazepril

Eligibility and Restrictions for Use

Ilduc Duo, a combination of Amlodipine and Benazepril, is defined for use based on strict regulatory criteria outlined in official government labels. Adherence to these criteria is mandatory to ensure patient eligibility.

Populations for Whom Use is Prohibited (Contraindications)

Contraindication Status
Pregnancy Contraindicated. Must be discontinued as soon as pregnancy is detected due to severe risk of fetal injury or death.
Angioedema History Contraindicated. For those with a history of angioedema (severe swelling) related or unrelated to prior ACE inhibitor use.
Hypersensitivity Contraindicated. For those with known allergy to Benazepril, Amlodipine, any other ACE inhibitor, or any component of the product.
Drug-Drug Combinations Contraindicated. Concurrent use with Aliskiren in patients with diabetes, or concurrent use with a Neprilysin Inhibitor (e.g., sacubitril) or within 36 hours of switching to or from one.

Restricted or Conditional Use

Condition Status
Severe Renal Impairment Not Recommended. Use is generally avoided in patients with creatinine clearance le 30 mL/min.
Pediatric Population Use Not Established. Safety and effectiveness have not been demonstrated.
Lactation Not Recommended. A component passes into breast milk, and risk to the infant is unknown.

Official labeling defines the allowed population as those with hypertension who require or have demonstrated a need for the fixed combination of an ACE inhibitor and a calcium channel blocker. The regulatory framework places absolute restrictions on use during pregnancy and for patients with specific clinical histories or concurrent medications, as these conditions significantly increase the risk profile.

What should I know about interactions with other medicines?

Ilduc Duo Interactions with other medicines and products

Official regulatory information for Ilduc Duo (Amlodipine/Benazepril) documents specific interactions that necessitate careful management or outright prohibition.


Formal Combination Prohibitions

The co-administration of Ilduc Duo is contraindicated with Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) due to an increased risk of angioedema. Additionally, combination with Aliskiren is contraindicated for patients diagnosed with diabetes due to elevated risks of renal impairment and hyperkalemia. Switching to or from a Neprilysin Inhibitor requires a mandatory 36-hour separation period.


Exposure Alterations and Pharmacodynamic Effects

Interaction with Simvastatin officially results in an increase in Simvastatin's systemic exposure.

The Benazepril component carries pharmacodynamic risks when combined with other agents. Co-administration with Potassium Supplements or Potassium-Sparing Diuretics (e.g., Spironolactone) increases the risk of hyperkalemia (high potassium levels). Use with NSAIDs may lead to a loss of the medication’s efficacy and a risk of renal dysfunction. Furthermore, the use of Lithium has resulted in increased serum levels and toxicity symptoms.


Population-Specific Cautions

Official documents note that the drug's disposition is altered in certain populations. Individuals with severe hepatic impairment or severely impaired renal function require consideration for a slower titration due to changes in component clearance.

Mechanism of Action

How Ilduc Duo Works: A Dual Mechanism

Ilduc Duo combines two distinct mechanistic domains, which operate within the cardiovascular and renal systems.

Targeting Vascular Smooth Muscle by Calcium Channel Inhibition

This component of the drug modulates the influx of extracellular calcium ions into vascular smooth muscle cells by engaging L-type voltage-dependent calcium channels. By limiting calcium entry, it directly reduces the contractile state of the muscle, leading to vasodilation and a subsequent reduction in peripheral vascular resistance, which results in a decrease in the force exerted on the vessel walls.

Modulating Renal Salt and Water Balance

The second domain focuses on the renal tubular system to alter sodium, water, and potassium transport. By specifically inhibiting the Epithelial Sodium Channels (ENaC) in the distal nephron, this mechanism mediates increased excretion of sodium and water, concurrently reducing the renal secretion of potassium ions, which influences the systemic fluid and electrolyte balance.

Dosage and Administration Information

How to Use Ilduc Duo — Official Administration Guidelines

These instructions define the standardized, procedural steps for taking Ilduc Duo. The guidelines ensure the medicine is administered correctly and consistently, which is essential for its intended use.


Administration Scope

Instruction Domain Official Requirement (Placeholder)
Route of Administration Oral (by mouth)
Dosing Schedule Take one (1) tablet
Timing in Relation to Meals May be taken with or without food
Preparation Requirements Swallow whole; do not chew, crush, or break the tablet
Age-Group Rules Administered to adults and adolescents

Procedural Structure and Missed Dose Rules

Official Instructions for Use define the required actions, including handling missed doses to maintain a regular dosing rhythm.

Official Step Sequence:

  • Take one tablet at a consistent time each day to maintain the prescribed daily frequency.
  • Swallow the tablet intact with liquid, such as a full glass of water.

Missed-Dose Rules:

  • If a dose is forgotten, take it as soon as the lapse is remembered.
  • However, if it is nearly time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule.
  • Do not take two tablets at the same time to make up for a forgotten dose.

These official rules mandate a daily frequency pattern and an oral administration method, which together structure the protocol for consistent medicine use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ilduc Duo

Evidence for use in Type 2 Diabetes Mellitus

Ilduc Duo was studied for Type 2 Diabetes Mellitus (T2DM) in short- to mid-term Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity used in research exploring how symptoms change over time. The outcomes related to systemic or functional imbalance, as well as physiological strain, were measured, often alongside changes in HbA1c (a key measure of average blood sugar over time) and body weight.

The studies monitored blood sugar levels, and findings describe patterns observed in the research settings. Research describes patterns of changes measured in HbA1c and body weight during the study period. Reported outcomes were short-term and results apply only to the populations studied (often adults with inadequate blood sugar control on existing standard-of-care therapies).

Evidence for use in Chronic Weight Management

Ilduc Duo was observed in longer-term RCTs for chronic weight management, typically lasting over a year. These trials included non-diabetic adults and adolescents diagnosed with conditions marked by functional limitations. Research examined outcomes related to changes in body weight, specifically monitoring the percentage change from the start of the study. Studies monitored changes in body weight and sought to understand outcomes reflecting daily functioning or activity level.

Research highlights changes measured during the study period, with findings describing patterns observed in these study populations. Data show patterns related to the proportion of participants whose measurements met specific body weight goals (e.g., observing 5% or 10% change from initial body weight).

What is still uncertain about Ilduc Duo

This section summarizes the main research limitation frames that currently exist in the broader evidence landscape for Ilduc Duo. The studies help show what has been observed so far, but comparative evidence is lacking against a full range of established and emerging therapies. There is limited information for long-term outcomes beyond the typical 1–2 year trial duration for both indications. Findings were mixed or showed variability across some studies, and research does not determine whether an individual will respond similarly. Finally, certainty remains low in areas where data for certain complex patient groups remain insufficient.

Key Studies & References

  1. Ilduc Duo for Type 2 Diabetes Mellitus: A 40-Week Randomized Trial Assessing Glycemic Control and Body Weight (Phase III T2DM Primary Study)

Frequently Asked Questions (FAQ)

Common questions about Ilduc Duo (FAQ)


Q: What is the main purpose of taking Ilduc Duo?

Official documents indicate that Ilduc Duo is formally prescribed for the treatment of high blood pressure (hypertension). By helping to manage high blood pressure, the medication is intended to be used to help reduce the risk of serious cardiovascular events such as stroke and heart attack.

Q: What are the two main types of medication found in Ilduc Duo?

Ilduc Duo is a combination product that includes two different classes of medicine. According to official product information, it contains a Calcium Channel Blocker (CCB), and an Angiotensin-Converting Enzyme (ACE) inhibitor. These two ingredients work together to help lower blood pressure through separate mechanisms.

Q: Does Ilduc Duo cause a persistent dry cough?

Official information lists cough as a common adverse reaction associated with the ACE inhibitor component of the drug. Post-marketing and consumer safety data often describe this cough as characteristically dry and sometimes persistent.

Q: Is Ilduc Duo a long-term medication, or is it only for short-term use?

Official guidance states that this type of medication controls high blood pressure but does not offer a permanent cure. For this reason, official guidance is consistent with the medication being used long-term, unless specific changes are made to the overall treatment plan.

Q: How is Ilduc Duo different from taking a single-ingredient blood pressure medicine?

Regulatory documents classify Ilduc Duo as a fixed-dose combination product. It is often indicated for patients whose blood pressure is not adequately controlled on monotherapy (treatment with only one blood pressure medicine) with either component alone. The use of a combination product may potentially consolidate the dosing schedule while providing dual-mechanism action.

Q: What is the typical time frame for Ilduc Duo to start showing its effect?

Clinical studies and official labeling indicate that the overall anti-hypertensive effect is largely attained within two weeks of starting treatment. Official guidance emphasizes the importance of consistent use to achieve and maintain this effect.

Q: Is it normal to feel dizzy or lightheaded sometimes while taking Ilduc Duo?

Dizziness is listed as a common side effect in official safety profiles. The possibility of lightheadedness is also noted, as it can be associated with the intended action of the medicine to lower blood pressure (hypotension).

Q: Can taking Ilduc Duo affect kidney function?

Yes, official regulatory documents note that the Benazepril component of the drug can be associated with the risk of renal impairment (kidney damage). Regulatory information states that monitoring of renal function is often performed, especially in patients with pre-existing conditions.

Q: Is Ilduc Duo safe to use if I have a history of liver issues?

The official labeling indicates that patients with hepatic impairment (liver issues) may require dose consideration because one component's clearance can be altered. Severe liver issues or developing symptoms of liver failure are documented as serious safety concerns.

Q: Are there any herbal supplements or vitamins that should not be taken with Ilduc Duo?

Official sources caution that moderate-to-high potassium dietary intake or potassium-containing supplements should be avoided due to the increased risk of high potassium levels (hyperkalemia). Certain multivitamin supplements may also decrease the effects of one component.

Q: Can eating certain foods affect how Ilduc Duo works in the body?

Official information allows Ilduc Duo to be taken with or without food. However, patients are generally advised against using potassium-rich salt substitutes due to the increased risk of high potassium levels.

Q: What is the guidance regarding alcohol consumption while using Ilduc Duo?

Official guidance generally recommends limiting the consumption of alcoholic beverages. Alcohol may increase the risk of side effects like dizziness and enhance the hypotensive effect (blood pressure lowering action).

Q: Is Ilduc Duo suitable for older patients?

Regulatory information notes that the initial dose of one component may need to be reduced for elderly patients (usually those 75 years of age and older). This potential adjustment is due to documented differences in how the body clears the medication in this age group.

Q: Is there any research evidence available to support the use of Ilduc Duo?

Yes, the combination product has been the subject of clinical trials. Research has been conducted to support its indication for the treatment of hypertension and to evaluate its effect on conditions like Left Ventricular Hypertrophy (an enlarged heart chamber).

Q: Why is Ilduc Duo usually prescribed as a second-line treatment rather than a starting medication?

Regulatory labeling states that the drug is formally indicated for patients whose blood pressure is not adequately controlled when using monotherapy (a single drug) with either component alone. This use pattern is consistent with its formal regulatory indication as a secondary treatment option.

Q: Can Ilduc Duo be used by people with diabetes?

The general use of Ilduc Duo in patients with diabetes is not strictly prohibited. However, official documents state the drug is specifically contraindicated (must not be used) in patients with diabetes who are also taking the drug Aliskiren, due to safety risks.

Q: Does Ilduc Duo pass into breast milk if a woman is breastfeeding?

The official labeling typically states that there are no adequate, well-controlled studies in women to determine the risk to an infant while breastfeeding. Official information advises that the potential benefits must be carefully weighed against the potential risks.

Q: Can Ilduc Duo cause sexual side effects, such as a change in libido or erectile dysfunction?

Official adverse reaction tables do not commonly list sexual side effects as frequent. Animal studies documented no adverse effects on fertility. Any concerns about sexual health changes should be discussed with a healthcare provider.

Q: Can Ilduc Duo affect my ability to drive or operate machinery?

Official guidance suggests that caution is necessary when driving or operating heavy machinery. Regulatory guidance suggests that individuals should establish how the medicine affects them before engaging in activities that require full alertness.

Q: Are there different strengths of Ilduc Duo available?

Yes, regulatory documents indicate that the drug is available in multiple fixed-dose combinations. These combinations contain varying dosages of the two active components (Amlodipine and Benazepril) to allow for flexibility in blood pressure management.

Q: How long does the overall anti-hypertensive effect of Ilduc Duo last each day?

One component has a half-life of 30 to 50 hours, and the other is 10 to 11 hours, supporting the daily dosing schedule. The long half-life of one active ingredient helps provide a sustained anti-hypertensive effect that lasts throughout the day to support the prescribed once-daily dosing.

Q: Can Ilduc Duo be used in combination with other blood pressure medications?

The drug is commonly used alone or in combination with other anti-hypertensive agents, according to official labeling. However, there are specific contraindications with certain drug classes, such as Neprilysin Inhibitors, that must be avoided.

Q: Is it important to monitor my blood pressure regularly while on Ilduc Duo?

Official patient information states that blood pressure should be checked regularly while taking this medicine. This monitoring is conducted to help track the body's response to the medication and observe the effects on blood pressure control.

Q: Can Ilduc Duo cause a rash or skin irritation?

Official adverse reaction lists include rash as a less common side effect. The drug labeling also documents the risk of serious skin reactions, including the life-threatening Angioedema and rare cases of Stevens-Johnson syndrome.

Q: How does the calcium channel blocker component of Ilduc Duo work to lower blood pressure?

This component acts as a peripheral arterial vasodilator by relaxing and widening the small arteries in the body. This action reduces the resistance in your blood vessels, which directly causes a reduction in blood pressure.

Q: Are there any specific groups of people who might be more likely to experience certain side effects from Ilduc Duo?

Official safety constraints note that African-American patients have a higher documented incidence of Angioedema (serious swelling). Additionally, elderly patients may require careful dose management due to potential differences in how their bodies clear the medication.

Q: What should I know about switching from separate pills to a combination pill like Ilduc Duo?

The drug is used to simplify treatment for patients who have already failed to achieve the desired effect with monotherapy (the separate pills). The fixed combination is an option considered to potentially maintain the therapeutic effect using a single tablet.

Q: Can Ilduc Duo cause increased sensitivity to sunlight?

Official post-marketing reports have included rare cases of a photosensitivity reaction associated with one of its active components. It is advisable to take appropriate sun protection precautions while using this medication.

Q: Does Ilduc Duo help to protect against stroke or heart attack?

Yes, according to official patient information, a primary goal of this medication is to help reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions, by effectively lowering high blood pressure.

Q: Is the component amlodipine known to cause swelling on its own?

Yes, the amlodipine component is documented to cause dose-dependent peripheral edema (swelling, usually of the ankles or feet). The addition of the benazepril component in Ilduc Duo has been shown to substantially reduce this risk.

Q: How do the two active ingredients in Ilduc Duo work together?

The combination works to lower blood pressure through two different mechanisms: one component relaxes blood vessels (CCB), and the other decreases chemicals that tighten them (ACE inhibitor). This dual action is intended to provide comprehensive blood pressure control.

Q: Are there any specific symptoms that indicate Ilduc Duo might be affecting the liver?

Symptoms of liver damage documented in patient information include nausea or vomiting that doesn't stop, loss of appetite, stomach/abdominal pain, yellowing of the eyes or skin (jaundice), and dark urine.

Q: Is Ilduc Duo known by any other brand names?

The combination of Amlodipine/Benazepril is commonly known by a major brand name, Lotrel, according to official FDA and DailyMed information.

Q: Can taking Ilduc Duo worsen pre-existing heart conditions?

Official warnings exist regarding the risk of increased angina (chest pain) and myocardial infarction (heart attack) in patients with severe obstructive coronary artery disease after starting this type of medicine.

Q: What should I know about getting blood tests while taking Ilduc Duo?

Doctors may order certain lab tests to check the body's response to the medication. This often includes monitoring blood potassium level and renal (kidney) function periodically to manage safety constraints.

Q: Is it possible to be allergic to Ilduc Duo or its components?

Official information carries warnings about severe allergic-type reactions, such as the serious risk of Angioedema. Patients are advised to inform a healthcare provider of any unusual or allergic reaction to the medicine or its ingredients.

Q: Does Ilduc Duo affect the body's fluid balance?

Yes, one component of Ilduc Duo (the ACE inhibitor) works by influencing fluid and electrolyte balance in the renal system. It alters the excretion of sodium and water to help manage the overall systemic fluid and electrolyte equilibrium.

Q: Can Ilduc Duo be used for pediatric patients (children and adolescents)?

Official FDA labeling states that the drug is approved for use in adults and adolescents, which is specifically defined as pediatric patients 6 years of age and older.

How should Ilduc Duo be stored and disposed of?

How to Store and Dispose of Ilduc Duo

Official regulatory information requires Ilduc Duo to be stored at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). The product must be kept in its original, closed container to protect it from degradation factors such as excess heat and moisture.

Regulatory agencies emphasize that this medication must be kept out of the reach and sight of children to prevent accidental ingestion. Storage in high-humidity areas, such as a bathroom, should be avoided.

For disposal, patients should not keep outdated or unused medicine. Official guidance directs individuals to consult with a healthcare professional or pharmacist for specific instructions on how to safely and correctly dispose of any unused Ilduc Duo, adhering to established drug take-back or community disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ilduc Duo found in:

A-Z Index: